4//SEC Filing
Dyrness Albert D. 4
Accession 0001493152-20-005838
CIK 0001106838other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 8:59 PM ET
Size
8.2 KB
Accession
0001493152-20-005838
Insider Transaction Report
Form 4
Dyrness Albert D.
Director
Transactions
- Award
Warrant to Purchase Common Stock
2020-04-01+1,279→ 1,279 totalExercise: $29.32From: 2020-04-01Exp: 2022-12-03→ Common Stock (1,279 underlying) - Award
Common Stock
2020-04-01+2,557→ 2,557 total
Footnotes (2)
- [F1]Shares of common stock of the corporation known as Sonnet BioTherapeutics, Inc. ("Sonnet Sub") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger, dated as of October 10, 2019, as amended, by and among the Issuer, Sonnet Sub and Biosub Inc., a Delaware corporation (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Sonnet Sub common stock was exchanged for approximately 0.106572 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Prior to the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 26 shares of Issuer common stock outstanding and the Issuer changed its name to Sonnet BioTherapeutics Holdings, Inc. All share numbers reflect the reverse stock split.
- [F2]Prior to the merger, Reporting Person held warrants to purchase 12,000 shares of the common stock of Sonnet Sub at an exercise price of $3.125 per share. Pursuant to the Merger Agreement, these warrants were converted into warrants to purchase 1,279 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $29.32 per share (as adjusted for the stock split).
Documents
Issuer
Sonnet BioTherapeutics Holdings, Inc.
CIK 0001106838
Entity typeother
Related Parties
1- filerCIK 0001664801
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 8:59 PM ET
- Size
- 8.2 KB